NCT04729309View on ClinicalTrials.gov

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

[12C] RO7049389

Participants will receive oral \[12C\] RO7049389.

DRUG

[13C] RO7049389

Participants will receive IV \[13C\] RO7049389.

DRUG

[14C] RO7049389

Participants will receive an oral suspension of \[14C\] RO7049389.

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04729309 - Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers | Biotech Hunter | Biotech Hunter